Kevin Cognetti
Vice President of Corporate Strategy Kite Pharma
Kevin Cognetti joined Kite in 2020 and currently serves as Vice President of Corporate Strategy and Planning.
Prior to joining Kite, Kevin held positions of increasing responsibility at Pfizer, including Vice President of Global Strategy for the Upjohn Division. During his tenure there, Kevin spearheaded the integration planning team for a $500M rare disease licensing deal and developed the strategy and operating model for Pfizer’s pivot to five core therapeutic areas. Before Pfizer, Kevin worked at McKinsey & Company, where he collaborated with Fortune 500 corporations on various growth and cost reduction strategies.
Seminars
Saturday 29th August 2026
Search, Evaluation & Investment Panel: Understanding the Role of in vivo Therapeutic in Shifting Investor & Pharma Strategies
4:00 pm
- Assessing how investors and pharma teams are integrating in vivo approaches into evolving pipeline and portfolio strategies
- Identifying the evidence and value inflection points shaping investment decisions for in vivo cell and gene therapy programs
- Aligning milestones, data packages and deal structures with shifting search, evaluation and investment priorities across the sector
Saturday 29th August 2026
Biopharma Leaders Fireside Chat: Clinical Reflections on the Past Year & Positioning In Vivo Cell & Gene Therapies in Pharma Portfolios
9:00 am
- Distilling the past year’s clinical and translational progress into portfolio-relevant proof points, sharpening investment, and resource allocation
- Prioritizing indications and modalities where in vivo approaches add differentiated value alongside existing assets, focusing pipeline sequencing
- Aligning global development routes, data portability, and CMC readiness with near-term regulatory and commercial realities, accelerating time to value
